Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
Each pathway contributes a separate pharmacological signal: GLP-1 receptor agonism slows gastric emptying and reduces appetite signalling in the hypothalamus GIP receptor agonism enhances glucose-dependent insulin secretion and is associated in the literature with effects on lipid handling Glucagon receptor agonism increases energy expenditure and hepatic glucose output, the opposite direction to a glucagon antagonist, and is absent from every dual agonist currently on the UK market How retatrutide compares to dual agonists Tirzepatide (Mounjaro) is a GIP + GLP-1 dual agonist authorised by the MHRA for type 2 diabetes in 2023
This formula absorbs instantly without leaving a sticky residue, yet imparts a subtle glow that lasts all day
Scientific Reports, 5 , 18325
alone, an estimated 11.3% of the population, equivalent to around 38.4 million individuals, are affected by DM, primarily Type 2 diabetes
